Event Description
Emcure Pharmaceuticals Limited executed Share Transfer Agreements on July 13, 2026 with all individual shareholders of Gennova Biopharmaceuticals Limited, its subsidiary, for acquisition of 663,865 Equity Shares. This represents 12.05% of the total issued and paid-up capital of Gennova.
Acquisition Details
- Shares Acquired: 663,865 Equity Shares
- Percentage Acquired: 12.05% of total issued and paid-up capital
- Current Holding: 87.95%
- Post-Acquisition Holding: 100% (making Gennova a wholly-owned subsidiary)
- Consideration: ₹2,318.7 Million payable in cash
- Payment Terms: Payable in one or more tranches on closing
- Completion Timeline: On or before July 31, 2026
Target Entity Information
Name: Gennova Biopharmaceuticals Limited
Business: Research and development, manufacturing and marketing of biotechnology-based products
Industry: Pharmaceuticals
Financial Information of Gennova
Turnover:
- FY 2025-26: ₹4,917.42 Million
- FY 2024-25: ₹4,299.46 Million
- FY 2023-24: ₹4,220.82 Million
Profit After Tax (FY 2025-26): ₹54.25 Million
Capital Structure:
- Authorized Share Capital: ₹650,000,000 (Rupees Six Hundred and Fifty Million only)
- Paid-up Share Capital: ₹55,113,650 (Rupees Fifty-Five Million One Hundred Thirteen Thousand Six Hundred and Fifty only)
Corporate History of Gennova
- Incorporated on June 19, 2001 as 'Emcure Dragon Biotech Limited'
- Name changed to 'Emcure Biotech Limited' on October 23, 2001
- Name changed to 'Gennova Biopharmaceuticals Limited' on February 15, 2006
Related Party Considerations
The transaction involves related parties as Gennova is currently a subsidiary (87.95% owned by Emcure). A Promoter and Director of Emcure is also a Director and Member of Gennova, and relatives of this Director who are Members of Gennova are considered related parties. The disclosure confirms the transaction is being undertaken at arm's length.
Regulatory Approvals
No governmental or regulatory approvals are required for this acquisition.
Geographic Presence
Gennova operates exclusively in India.
#Tags: #Emcure #Gennova #SEBIRegulation30 #Acquisition #Subsidiary #Neutral